6 November 2024 - NICE has published evidence-based recommendations on the use of avapritinib (Ayvakyt) for the treatment of adults with advanced systemic mastocytosis.

Avapritinib is recommended as an option for the treatment of adults with advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm and mast cell leukaemia). 

Avapritinib is only recommended if Blueprint Medicines provides it according to the commercial arrangement.

Read NICE technology appraisal guidance